Mangafodipir
Mangafodipir Uses, Dosage, Side Effects, Food Interaction and all others data.
Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. This drug is made up of paramagnetic manganese (II) ions combined with the chelating agent fodipir (dipyridoxyl diphosphate, DPDP). Manganese absorption into the tissues that makes the normal tissue appear brighter in MRI is limited in abnormal or cancerous tissue. Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas. The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan. Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.
Manganese (II) metals exhibit paramagnetic properties that increases contrast between normal liver parenchyma and metastatic liver lesions after uptake into the hepatic or pancreatic parencyma. They serve to increase the signal intensity of liver or pancreas tissue. Enhancement in both organs is near maximal for up to approximately 4 hours after the end of administration. Lesion-related enhancement of certain types of lesions, such as liver metastases and hepatocellular carcinomas, may be detectable for up to 24 hours .
| Trade Name | Mangafodipir |
| Availability | Discontinued |
| Generic | Mangafodipir |
| Mangafodipir Other Names | Mangafodipir |
| Type | Intravenous |
| Formula | C22H30MnN4O14P2 |
| Weight | Average: 691.382 Monoisotopic: 691.06142 |
| Protein binding | The protein binding of manganese is approximately 27% but negligible for fodipir . Manganese is transported to the liver via α2-macroglobulin and to a lesser extent, albumin . |
| Groups | Approved, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Mangafodipir is an organ-specific paramagnetic contrast agent indicated for the imaging of the hepatobiliary system and detecting lesions in the liver and pancreas.
Indicated for use as an organ-specific paramagnetic contrast agent developed for imaging of the hepatobiliary system and detecting lesions in liver and pancreas.
Mangafodipir is also used to associated treatment for these conditions: Hepatic Lesions
How Mangafodipir works
After intravenous administration, the chelate dissociates slowly to manganese and organic ligand fodipir (dipyridoxyl diphosphate), and manganese is taken up by the hepatocytes with high affinity and selectivity. The ligand fodipir is distributed to the extracellular fluid and later eliminated via urine . Mangafodipir shortens the longitudinal relaxation time (T1) of targeted tissues during MRI, where signal intensity or brightness is increased in normal liver parenchyma. Overall, there is increased contrast between normal tissue and abnormal tissue with lesions because there is a difference between cellular compositions , and manganese uptake in metastatic tissue or focal lesions is minimal or nearly absent .
Toxicity
Common adverse effects include headache, nausea and feeling of warmth or flushing. Other uncommon side effects include hypersensitivity reactions, fever, diarrhea, vomiting, dizziness, palpitations, paraesthesia, abdominal pain, and taste sensations. There is no identified antidote in case of overdose. Mangafodipir displays embryotoxic and fetotoxic potential thus is contradindicated in pregnant patients. It is not reported to be genotoxic . LD50 in the mouse is 5 mmol/kg .
Food Interaction
No interactions found.Volume of Distribution
The volume of distribution for manganese is between 0.5 and 1.5 l/kg, and 0.17 to 0.45 l/kg for fodipir (dipyridoxyl diphosphate) . Fodipir is distributed rapidly throughout the body with the highest concentrations in the kidneys, lung, blood and liver with a low affinity in the myocardium and brain. Manganese is initially distributed to the kindeys and sequentially to liver, spleen and pancreas .
Elimination Route
Mangafodipir is taken up by the liver and pancreas where the contrast enhancement effect is mediated.
Half Life
The mean initial plasma half-life of manganese metals is approximately 20 minutes and 50 minutes for fodipir (dipyridoxyl diphosphate, DPDP) .
Clearance
The approximate total clearance of radiolabeled mangafodipir is 3.1 mL/min kg in dogs .
Elimination Route
Fodipir is predominantly eliminated via urine within 24 hours where up to 25% of administered fodipir is excreted into feces. Manganese is mainly excreted into feces where renal elimination is about 15-20% of the dose .
Innovators Monograph
You find simplified version here Mangafodipir
